AC Immune (ACIU) Stock Forecast & Price Target

AC Immune is attractive fundamentally because it has multiple shots on goal across Alzheimer’s, Parkinson’s, and inflammatory neurodegeneration, backed by proprietary active immunotherapy, Morphomer, and diagnostic platforms that can lower treatment burden versus IV monoclonal antibodies. The lead ACI-24.060 program has shown 100% responder rate, robust CSF penetration, clean safety with no ARIA-E events, and anti-amyloid antibody responses across doses, while 12-month data from AD1–AD3 are expected in Q2 2026 and could unlock meaningful partner value, including Takeda milestones and royalties. Its partnered economics and pipeline optionality are further strengthened by a $100 million upfront from Takeda, eligibility for up to about $2.1 billion in additional milestones, and the prospect that ACI-7104 and the NLRP3 program could validate disease-modifying biology with transformatively scalable, orally or vaccine-based approaches.

AC Immune is facing a fundamentally challenging profile because its pipeline remains heavily dependent on clinical-stage programs with uncertain translation from biomarker activity to meaningful cognitive benefit, and the excerpts explicitly note that ACI-24.060 may be “close, but not quite enough” on plaque removal despite a new cohort and possible two-year wait for the next data. The company’s other assets also carry substantial execution risk, including ACI-35.030 with only 35% PoS and a 2031 market entry assumption, while the next data for the NLRP3 program are mainly safety and CNS-penetration checks rather than proof of efficacy. With limited near-term de-risking, lower-than-optimal immunogenicity in vaccines, and a need for higher antibody levels to translate into clinical effects, the outlook remains negative on weak fundamental visibility.